Rita Faria

2.8k total citations · 2 hit papers
47 papers, 1.7k citations indexed

About

Rita Faria is a scholar working on Economics and Econometrics, General Health Professions and Surgery. According to data from OpenAlex, Rita Faria has authored 47 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Economics and Econometrics, 15 papers in General Health Professions and 8 papers in Surgery. Recurrent topics in Rita Faria's work include Health Systems, Economic Evaluations, Quality of Life (20 papers), Geriatric Care and Nursing Homes (7 papers) and Lipoproteins and Cardiovascular Health (4 papers). Rita Faria is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (20 papers), Geriatric Care and Nursing Homes (7 papers) and Lipoproteins and Cardiovascular Health (4 papers). Rita Faria collaborates with scholars based in United Kingdom, Spain and Canada. Rita Faria's co-authors include David Epstein, Manuel Gomes, Mark Sculpher, Ian R. White, Claire McKenna, Nerys Woolacott, Rachel Elliott, Dina Janković, Elizabeth Camacho and Ros Wade and has published in prestigious journals such as SHILAP Revista de lepidopterología, European Urology and British journal of surgery.

In The Last Decade

Rita Faria

43 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Guide to Handling Missing Data in Cost-Effectiveness Analysis Conducted Within Randomised Controlled Trials

2014 388 citations Rita Faria, Manuel Gomes et al. PharmacoEconomics profile →
Economic analysis of the prevalence and clinical and economic burden of medication error in England

2020 207 citations Mark Sculpher, Rita Faria et al. profile →

Peers

Countries citing papers authored by Rita Faria

Since Specialization

Citations

This map shows the geographic impact of Rita Faria's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rita Faria with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rita Faria more than expected).

Fields of papers citing papers by Rita Faria

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rita Faria. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rita Faria. The network helps show where Rita Faria may publish in the future.

Co-authorship network of co-authors of Rita Faria

This figure shows the co-authorship network connecting the top 25 collaborators of Rita Faria. A scholar is included among the top collaborators of Rita Faria based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rita Faria. Rita Faria is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Attributes and Health Care Resource Utilization of Patients on Enzalutamide or Abiraterone for Metastatic Castration-Resistant Cancer in England 2025 ·JCO Oncology Practice ·Amit Bahl, Rita Faria, Axel S. Merseburger, Gerhardt Attard, Robert Snijder, (unknown), (unknown), (unknown), (unknown), Nigel Rozario, (unknown), (unknown)	1
2	Challenges and opportunities for identifying people with familial hypercholesterolemia in the UK: Evidence from the National FH PASS database 2024 ·Journal of clinical lipidology ·Edward Cox, Rita Faria, Pedro Saramago, (unknown), Melanie Watson, Steve E. Humphries, Nadeem Qureshi, Beth Woods	2
3	Economic evaluation of self-help group interventions for health in LMICs: a scoping review 2023 ·Health Policy and Planning ·Jessica Ochalek, (unknown), Rita Faria, Joydeepa Darlong, (unknown), Melissa Harden, Anthony Meka, (unknown), (unknown), Richard Lilford, Mark Sculpher	0
4	Alternative cascade-testing protocols for identifying and managing patients with familial hypercholesterolaemia: systematic reviews, qualitative study and cost-effectiveness analysis 2023 ·Health Technology Assessment ·Nadeem Qureshi, Beth Woods, Rita Faria, Pedro Saramago, Edward Cox, Jo Leonardi‐Bee, Laura Condon, Stephen Weng, Ralph Kwame Akyea, Barbara Iyen, Paul Roderick, Steve E. Humphries, William N. Rowlands, Melanie Watson, (unknown), (unknown), D. Datta, Zosia Miedzybrodzka, Christopher D. Byrne, Joe Kai	2
5	How does cholesterol burden change the case for investing in familial hypercholesterolaemia? A cost-effectiveness analysis 2022 ·Atherosclerosis ·Rita Faria, Pedro Saramago, Edward Cox, Stephen Weng, Barbara Iyen, Ralph Kwame Akyea, Steve E. Humphries, Nadeem Qureshi, Beth Woods	3
6	Cost-effectiveness of 5 fraction and partial breast radiotherapy for early breast cancer in the UK: model-based multi-trial analysis 2022 ·Breast Cancer Research and Treatment ·(unknown), Judith M. Bliss, Adrian Murray Brunt, Charlotte E. Coles, Duncan Wheatley, Joanne Haviland, Anna M. Kirby, (unknown), Rita Faria, John Yarnold, Susan Griffin	15
7	Effectiveness of cascade testing strategies in relatives for familial hypercholesterolemia: A systematic review and meta-analysis 2021 ·Atherosclerosis ·Jo Leonardi‐Bee, (unknown), Rita Faria, (unknown), Ben Young, Nadeem Qureshi	10
8	Avoiding Opportunity Cost Neglect in Cost-Effectiveness Analysis for Health Technology Assessment 2021 ·Applied Health Economics and Health Policy ·James Lomas, Jessica Ochalek, Rita Faria	11
9	Antimicrobial-impregnated central venous catheters for preventing neonatal bloodstream infection: the PREVAIL RCT 2020 ·Health Technology Assessment ·Ruth Gilbert, Michaela Brown, Rita Faria, Caroline Fraser, Chloe Donohue, Naomi Rainford, (unknown), Ajay Sinha, Jon Dorling, J. Gray, Berit Müller‐Pebody, Katie Harron, Tracy Moitt, (unknown), Laura Bojke, Carrol Gamble, Sam Oddie	12
10	Cost-effectiveness of strategies preventing late-onset infection in preterm infants 2019 ·Archives of Disease in Childhood ·(unknown), Rita Faria, Laura Bojke, Chloe Donohue, Caroline Fraser, Katie Harron, Sam Oddie, Ruth Gilbert	7
11	Ciência à medida: conflitos de interesse e interferência na investigação científica financiada 2018 ·SHILAP Revista de lepidopterología ·Rita Faria	2
12	RM1 - SENSITIVITY ANALYSIS FOR NOT-AT-RANDOM MISSING DATA IN TRIAL-BASED COST-EFFECTIVENESS ANALYSIS USING MULTIPLE IMPUTATION 2018 ·Value in Health ·Baptiste Leurent, Manuel Gomes, Rita Faria, Stephen Morris, Richard Grieve, James R. Carpenter	0
13	Models of reablement evaluation (MoRE): a study protocol of a quasi-experimental mixed methods evaluation of reablement services in England 2016 ·BMC Health Services Research ·Rachel Mann, Bryony Beresford, Gillian Parker, Parvaneh Rabiee, Helen Weatherly, Rita Faria, Mona Kanaan, (unknown), (unknown), Fiona Aspinal	13
14	The Challenges in Evaluating the Cost-Effectiveness of Complex Interventions 2015 ·Value in Health ·Rita Faria, Helen Weatherly, (unknown), Andrea Manca, Gillian Parker, Bryony Beresford, Gerlinde Pilkington, (unknown), Mona Kanaan, Parvaneh Rabiee, Rachel Mann, Fiona Aspinal	2
15	A multicentre randomised controlled trial and economic evaluation of continuous positive airway pressure for the treatment of obstructive sleep apnoea syndrome in older people: PREDICT 2015 ·Health Technology Assessment ·Alison McMillan, Daniel J. Bratton, Rita Faria, Magda Laskawiec-Szkonter, Susan Griffin, Robert J.O. Davies, Andrew Nunn, John Stradling, Renata L. Riha, Mary J. Morrell	42
16	Optimizing the Position and Use of Omalizumab for Severe Persistent Allergic Asthma Using Cost-Effectiveness Analysis 2014 ·Value in Health ·Rita Faria, Claire McKenna, Stephen Palmer	27
17	Real-World Verse Randomised Controlled Trial Data: A Case Study On The Cost-Effectiveness Of Laparoscopic Surgery For Chronic Reflux 2014 ·Value in Health ·Rita Faria, (unknown), David Epstein, Andrea Manca	1
18	Dabigatran for the Prevention of Stroke and Systemic Embolism in Atrial Fibrillation: A NICE Single Technology Appraisal 2013 ·PharmacoEconomics ·Rita Faria, Eldon Spackman, Jane Burch, Belén Corbacho, Derick Todd, Chris Pepper, Nerys Woolacott, Stephen Palmer	14
19	PRM19 Something for Nothing? The Value of Informal Care 2012 ·Value in Health ·Rita Faria, Helen Weatherly, Bernard van den Berg	1
20	A systematic review of the clinical effectiveness of EOS 2D/3D X-ray imaging system 2012 ·European Spine Journal ·Ros Wade, Huiqin Yang, Claire McKenna, Rita Faria, N Gummerson, Nerys Woolacott	80

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact